Diabetes Connections | Type 1 Diabetes

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: infusion set recall, update on ViaCyte stem cell research, a few new studies look at sleep and diabetes, actual clinical research into cinnamon for type 1 and lots more. Links & transcript below Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected] Episode transcript: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX Our top story this week… XX A recall of infusion sets. This is the VariSoft infusion set used with Tandem Diabetes Pumps. The recall here isn't new.. but the FDA has changed the rating to Class 1, its most serious. The VariSoft version is flexible and can be put in place at an insertion angle anywhere between 20 and 45 degrees, it's usually recommended for people "who are thin or who have scar tissue or limiting potential insertion sites." The problem is that the connector can detach from the set – which means no insulin is going in. To date, according to the FDA notice, there has only been one report of injury related to the recall. https://www.fiercebiotech.com/medtech/fda-gives-class-i-recall-rating-infusion-sets-used-tandem-insulin-pumps XX An already existing drug may help preserve beta cell function in people with new onset type 1. It's got a very long name, so it's usually referred to as DFMO. It inhibits a pathway, which plays a role in the inflammatory responses in autoimmune diseases, including type 1 diabetes. It's sold under a few names for different conditions, including Vaniqa which is a cream for unwanted hair growth in women. It also has orphan designations for treating various cancers, including neuroblastoma. The new safety study by Sims and colleagues, which was published November 1 in Cell Medicine Reports, enrolled 41 people with type 1 diabetes that had been diagnosed within the previous 8 months, including 31 children. Participants were randomly assigned to undergo oral treatment with DFMO at one of five doses or placebo for 3 months, with 3 additional months of follow-up. Following a mixed-meal tolerance test at 6 months, the C-peptide area under the curve ― a measure of beta-cell function ― was significantly higher with the three highest DFMO doses compared to placebo (P = .02, .03, and .02 for 125 mg/m2, 750 mg/m2, and 1000 mg/m2, respectively). https://www.medscape.com/viewarticle/998671?form=fpf XX Despite earlier promising findings, it seems unlikely that cinnamon can improve blood sugar levels in people with type 1, or insulin-dependent, diabetes, researchers report. Previous research has shown that cinnamon appears to help fat cells recognize and respond to insulin. In test tube experiments and in animal studies, the spice led to a noteworthy increase in the processing of glucose. Moreover, in a previous study of people with type 2, or non-insulin dependent, diabetes, those who incorporated a small amount of cinnamon each day for 40 days into their normal diets experienced a healthy drop in blood sugar levels. But a new study of teenagers with type 1 showed cinnamon made no difference after 90 days . In fact, "In essentially all outcomes...the trend favored the placebo group, although did not achieve statistical significance," the researchers report. https://www.reuters.com/article/us-cinnamon-diabetes-idUSSIB65463020070406/ XX New results from ViaCyte clinical trials – that's a stem cell-based treatment for type 1 diabetes. The therapy aims to replace the insulin-producing beta cells that people with type 1 diabetes lack. Dubbed VC-02, the small medical implant contains millions of lab-grown pancreatic islet cells, including beta cells. The devices—approximately the size of a Band-Aid and no thicker than a credit card—are implanted just beneath a patient's skin where it is hoped they will provide a steady, long-term regulated supply of self-sustaining insulin. The clinical trial was conducted at Vancouver General Hospital, with additional sites in Belgium and the U.S. Ten participants, each of whom had no detectable insulin production at the start of

At Moms' Night Out Providence, I was part of an Ask Us Anything panel that included Moira McCarthy and Kerri Sparling. We had a lot of fun on this panel and a lot of fun at MNO period. If you're wondering what this event is all about, I think this panel will give you a lot of insight. It's serious, and humorous, I hope helpful, and it's all peer to peer – we're not doctors. Moira McCarthy's daughter, Lauren, was marking 26 years with T1D during this event! Moira is a ski, adventure and travel writer. A JDRF International Volunteer of the Year and author of six books including, "Raising Teens with Diabetes." Her blog Despite Diabetes helped me a lot and she's left it up as a resource. Kerri Sparling is a writer, poet and speaker who has dedicated her life to the power of the patient narrative. Best known for the blog and book, "SixUntilMe," she is the author of "Balancing Diabetes" and "Rage Bolus and other poems." Kerri has lived with type 1 for 37 years. Our next MNO is in Charlotte in February This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

This week, Mila Clark became a popular advocate for type 2 diabetes after her diagnosis in 2016 But she was actually one of the many adults misdiagnosed – she actually lives with LADA. One of the biggest changes she experienced was how her health care providers treated her, they were much more supportive when they realized she had LADA – also called type 1.5. Mila is working to reduce the stigma around all types of diabetes. We talk about her advocacy, her Hangry Woman business, the unique patch pump she's using and a lot more. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about LADA Our previous episode with Mila here Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

Do you know your rights with diabetes? Our guest this week is John Griffin, a trial lawyer with more than 30 years of advocating in and out of the courtroom. He lives with type 2 himself – this is an eye opening and useful conversation. Griffin served as National Chair of the Board of the American Diabetes Association in 2011, and is the former Chair of the Association's Legislative and Regulatory Subcommittee. Also, if you've been given a blood glucose meter you probably know how to use it, but do you know how it works? We'll explain the chemistry going on here This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. More information about how your glucose meter works: More about c-peptide The information explaining Metformin comes from DiaTribe Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up today (no spam we promise) Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: Novo Nordisk will discontinue Levemir by the end of 2024, Tandem begins limited launch of software updates that will include Dexcom's G7, Beta Bionics iLet pump will be covered until some pharmacy plans, and lots more! Links and transcript below Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected] Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX This week was World Diabetes Day so there is a LOT going on.. Our top story is XX Novo Nordisk said on Wednesday it would discontinue its long-acting insulin Levemir in the United States, citing manufacturing constraints, reduced patient access and available alternatives. The Danish drugmaker said supply disruptions would start in mid-January, followed by discontinuation of the Levemir injection pen in April and of Levemir vials by the end of 2024. Novo has another long-acting insulin, Tresiba, on the market and says quote - "global manufacturing constraints, significant formulary losses impacting patient access effective in January 2024, and the availability of alternative options in the U.S. market" are key factors in the decision. The announcement comes eight months after Novo said it would cut U.S. list prices for several of its insulin products next year, including a 65% reduction in the list price of Levemir. Novo, which overtook LVMH (LVMH.PA) as Europe's most valuable listed company this year, posted record operating profit for the third quarter, with sales of its obesity drug Wegovy reaching $1.36 billion, up 28% from the previous quarter. https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-discontinue-levemir-insulin-us-market-2023-11-08/ XX Big news from Tandem Diabetes this week – first, their Control IQ algorithm gets FDA approval for children as young as two years old. the technology's original 2019 clearance limited its use to those aged 6 and older. And.. they are officially rolling out the software update that will allow users to connect to either the Dexcom G6 or G7 CGM. If you're in the limited launch you got an email this week telling you the next steps – wider release is expected gradually in the first part of 2024. Integration with Abbot's FreeStyle Libre is expected very soon as well – which would mean Tandem's tslim x2 and Mobi pumps would be compatible with three CGMs. Full disclosure: there wasn't a media release that I received on this, but my son is in the limited launch group so we got the email. https://www.fiercebiotech.com/medtech/tandem-diabetes-care-cruises-fda-ok-toddler-use-automated-insulin-delivery-algorithm XX Beta Bionics iLet pump and its supplies are now covered as part of some pharmacy benefits - Express Scripts added it to its national formulary list. Historically, insulin pumps fall under the durable medical equipment (DME) insurance benefit. Usually pharmacy benefits are more flexible with fewer up front costs. The system uses an adaptive, closed-loop algorithm that initializes with the user's body weight and requires no additional insulin dosing parameters. The algorithm removes the need to manually adjust insulin pump therapy settings and variables. iLet simplifies mealtime use by replacing conventional carb counting with its meal announcement feature. This enables users to estimate the amount of carbs in their meal, categorized as "small," "medium" or "large." Over time, the algorithm learns to respond to users' individual insulin needs. https://www.drugdeliverybusiness.com/beta-bionics-pharmacy-benefit-bionic-pancreas/ XX The UK has launched a pioneering study to explore the development of type 1 diabetes in adults which aims to screen 20,000 individuals. Research will enable earlier and safer diagnosis of type 1 diabetes through blood tests. This makes the UK the first country to implement general population screening for type 1 diabetes in both children and adults. The Type 1 Diabetes Risk in Adults (T1DRA) study, launched on World Diabetes Day, seeks to enroll 20,000 adults aged

At Moms' Night Out Providence, I was part of an Ask Us Anything panel that included Moira McCarthy and Kerri Sparling. We had a lot of fun on this panel and a lot of fun at MNO period. If you're wondering what this event is all about, I think this panel will give you a lot of insight. It's serious, and humorous, I hope helpful, and it's all peer to peer – we're not doctors. Moira McCarthy's daughter, Lauren, was marking 26 years with T1D during this event! Moira is a ski, adventure and travel writer. A JDRF International Volunteer of the Year and author of six books including, "Raising Teens with Diabetes." Her blog Despite Diabetes helped me a lot and she's left it up as a resource. Kerri Sparling is a writer, poet and speaker who has dedicated her life to the power of the patient narrative. Best known for the blog and book, "SixUntilMe," she is the author of "Balancing Diabetes" and "Rage Bolus and other poems." Kerri has lived with type 1 for 37 years. Our next MNO is in Charlotte in February This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

Dr. Mike Natter took a non-traditional path to becoming an endocrinologist, starting out as an art student. But it turns out, the universal language of drawing can help break down barriers Mike lives with type 1 – he was diagnosed at age 9. This is a wide ranging interview, we talk about his diagnosis at age 9, finishing his medical residency in NYC during the height of COVID, what he learned from his test run with the new Beta Bionics iLet pump, and a lot more. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

This is the first episode of our new show, Diabetes Connections TYPE 2. Here's what we're talking about: What IS an A1C? What you need to know about this all-important number. My guest is a sports photographer and journalist. We're going to talk about what it takes to do that job and how he was diagnosed with diabetes after a tough run in with the Texas heat.. And hey this is our first episode – we'll get to know each other a little bit. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. -- A1C information from: The Mayo Clinic and the American Diabetes Assocation More about the history of Diabetes Awareness Month & World Diabetes Day -- Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up today (no spam we promise) Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: a new study looks at pancreatic exocrine-endocrine "crosstalk," weekly basal for T1D moves forward, a Chinese company gets European approval for its CGM, a look at air pollution as a cause of T2D, lots of info and advocacy for Diabetes Awareness Month including some movies and documentaries. Links and transcript below Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected] Episode Transcript: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX It's Diabetes Awareness Month so you're going to see a lot of advocacy posts and hear about all types of diabetes and technology and advances. It's always diabetes awareness month around here, so I'm not going to talk about each and every one of these campaigns.. but I'll share more on social. XX Our top story this week, In the largest study of its kind, researchers at Vanderbilt University Medical Center have identified unexpected alterations in the exocrine tissues of the pancreas that occur in the two major forms of diabetes, and with aging and obesity. They're calling this a report on pancreatic exocrine-endocrine "crosstalk." I'm not going to do it justice, it's pretty complex, so please check out the show notes with all the links. They say their work, published in the journal Diabetes, represents a significant advance in understanding how Type 1 and Type 2 diabetes, alter the digestive enzyme-secreting exocrine portion of the pancreas. Not just the parts that make insulin. The pancreas has been very difficult to study because it is surrounded by other vital organs, hard to access, and it quickly deteriorates. Pancreas tissue for study must come from deceased donors or fragments of surgical specimens and those are hard to come by. This group says they were able to study an unprecedently large and well-preserved group of tissue samples from 119 donors. https://news.vumc.org/2023/11/01/pancreas-crosstalk-may-influence-course-of-type-1-and-type-2-diabetes/#:~:text=VUMC%20Reporter-,Pancreas%20%E2%80%9Ccrosstalk%E2%80%9D%20may%20influence%20course%20of%20Type,1%20and%20Type%202%20diabetes&text=In%20the%20largest%20study%20of,and%20with%20aging%20and%20obesity. XX Another promising study about Insulin icodec, a once-weekly basal injection – this time for type 1 diabetes. We've been following this for a while and the results of the year-long phase 3 clinical trial are in. After 26 weeks, once weekly basal looks just about the same as daily basal in terms of overall diabetes control. The group that received daily injections had their A1Cs go down to 7.1, the group that got the weekly basal was at 7.15. These researchers say it's very promising, but further analysis of CGM data and real world studies are needed to keep moving forward. https://www.technologynetworks.com/drug-discovery/news/weekly-insulin-for-type-1-diabetes-has-the-potential-to-be-as-effective-as-daily-regimens-trial-380487 XX air pollution raises risk of type 2 diabetes, says a landmark study out of India. This was a seven year study of 12,000 people and showed Inhaling polluted air increases the risk of type 2 diabetes, the first study of its kind in India has found. When inhaled, PM2.5 particles – which are 30 times thinner than a strand of hair – can enter the bloodstream and cause several respiratory and cardiovascular diseases. India is one of the worst countries in the world for air pollution. These researchers say "Until now, we had assumed that diet, obesity and physical exercise were some of the factors explaining why urban Indians had higher prevalence of diabetes than rural Indians," said Dr V Mohan, chairman of the Madras Diabetes Research Foundation and one of the authors of the paper. "This study is an eye-opener because now we have found a new cause for diabetes that is pollution." https://www.theguardian.com/global-development/2023/nov/01/air-pollution-raises-risk-of-type-2-diabetes-says-landmark-indian-study-acc XX Time-restricted eating, also known as intermittent fasting, can he

Tandem's tiny Mobi pump is FDA approved and set for a limited roll out in the next few weeks. We've got a deep dive into its features. Mobi is phone controlled, but it has a button that delivers insulin and more.. This week we're talking with Ben Mar, Tandem's Director of Product Marketing. We go through all of those features, answer a bunch of your questions about Mobi and about what else is coming up for Tandem. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. More about Mobi: https://www.tandemdiabetes.com/ Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

It's been five years since Ryan Reed has been behind the wheel at a NASCAR track. He raced in Vegas earlier this month as part of the Xfinity Cup Series. We talked about what's changed for his T1D management, how he handles diabetes & driving, why he's changed to a pump since we last talked and much more. Reed also explains why he appreciates the diabetes community now more than ever. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Our previous episodes with Ryan Reed (and one with his mom!) Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: new studies on the safety and efficacy of what's called the pill form of drugs like Ozempic and Mounjaro, a new study says it may be possible to diagnose a person with type 2 just by recoding their voice, the latest on Tzield, the only drug shown to stave off type 1 for any length of time, how a vegan diet impacts people with T1D, one of the team who discovered insulin gets a long-due honor, and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected] Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX The next step in GLP-1 research is focusing on oral medications. new study looking at two different versions danuglipron dag-NEW-la-pron and orforglipron ah-for-GLOO-pron The primary examined outcome consisted of how different the absolute changes in the percentage of glycated hemoglobin (HbA1c) from baseline were between the treatment and control groups. Secondary outcomes included endpoint differences in body weight, fasting plasma glucose (FPG), systolic and diastolic blood pressure, body mass index (BMI), and heart rate between the treatment and control groups when absolute changes from baseline values were measured. The preliminary findings indicated that the orally administered small molecule GLP-1RAs danuglipron twice daily from Pfizer and orforglipron once a day from Lilly were effective in weight reduction and glycemic control in individuals with type 1 diabetes, obesity, or both. As compared to the controls, the novel small molecule GLP-1RAs not only resulted in a significant lowering of HbA1c levels in patients with type 2 diabetes mellitus but in patients with obesity and type 2 diabetes, danuglipron and orforglipron also brought about significant weight reduction. While the safety profiles indicated that the orally administered danuglipron and orforglipron did not increase the odds of serious adverse reactions or hypoglycemic events, the odds of adverse gastrointestinal events such as diarrhea, nausea, constipation, and vomiting were higher. These adverse gastrointestinal events were also linked to higher odds of treatment discontinuation. Further, longitudinal studies are required to understand these treatment options' long-term efficacy, tolerability, and safety. https://www.news-medical.net/news/20231017/Oral-diabetes-and-obesity-meds-danuglipron-and-orforglipron-show-promise-but-have-gastrointestinal-drawbacks.aspx XX More news about Tzield to slow type 1 progression in newly diagnosed children and adolescents. Data from the Phase III PROTECT clinical trial, presented at the 2023 Annual ISPAD Conference, showed that superior beta cell preservation was observed compared to placebo. On average, patients administered with TZIELD required numerically fewer insulin units and had numerically higher time in range, compared to those on placebo. HbA1c reductions and the overall rates of clinically important hypoglycemic events were similar among both study groups. TZIELD is the first and only disease modifying therapy in type 1 diabetes An observational extension study following participants for a further 42 months is ongoing. Release of the PROTECT trial data follows the company's acquisition of Provention Bio (a Sanofi Company) in April 2023 and therefore represents a key milestone for Sanofi. https://www.europeanpharmaceuticalreview.com/news/187735/sanofi-treatment-could-slow-type-1-diabetes-progression/ XX Lots of speculation about what the growing popularity of new diabetes drugs will do to the device market. Abbott says they're doing just fine.. and that the treatments could end up boosting sales of the medical device maker. Shares have dropped with concerns that GLP-1 drugs like Ozempic and Mounjaro could hurt CGM sales. Abbott says their sales are actually up this year. Now, grain of salt, because this is press release info.. but it's worth noting that the device market is very important to people who use pump systems of course. Most diabetes device analysts do seem to agree with Abbott here. https://www.reuters.com/busine

Going to college with type 1 is a big adjustment. Going to college as a student athlete with type 1 is on another level. You'll hear from Syracuse University rower Tristan Wakefield about his schedule, how he manages T1D and how he and his parents worked ahead of time to make the transition as smooth as possible. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about Moms' Night Out More about the NIL policy here: https://www.ncsasports.org/name-image-likeness More about Dexcom U here: https://www.dexcom.com/en-us/dexcomu Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

A new movie's in the works about diabetes called "The Cost". It's fictional, a thriller co-written and directed by Mike Hogan who lives with type 1. Mike explains more about what the movie is about, how you can help it get made, and what it's been like following a childhood dream that doesn't include health insurance. More info about The Cost here Contact Mike directly at [email protected] This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: lots of news from the EASD conference, including info from Dexcom, Vertex, and more, the ADA issues new guidelines for CGM use at school around caregivers' ability to follow, a new study says women should be screened at a younger age for type 2 diabetes, and congrats to Lauren Dahlin, who lives with type 1, for qualifying for the Ironman race in Hawaii. Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected] Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX Lots of news out of EASD – the European Association for the Study of Diabetes happening this week. Including, a new trial finds that antiviral medications, when given soon after a child is diagnosed with type 1 diabetes, might help preserve those vital beta cells. The team followed 96 children aged 6 to 15 who were all diagnosed with type 1 diabetes within three weeks prior to their enrollment in the study. The children were randomly selected to receive either the two antiviral medicines or a placebo for six months. After one year of follow-up, the researchers found that C-peptide levels remained "significantly higher" in kids who'd gotten the antiviral treatment compared to those who hadn't. That suggests the treatment helped shield the child's pancreatic beta cells from destruction. While C-peptide levels dropped a full 24% in children who received the placebo, it fell by just 11% in those who got the antivirals, the investigators found. On top of that, 86% of kids who'd gotten the antivirals still produced their own insulin at a level that makes treatment with supplementary insulin easier, the team said, and is also known to be linked to lowered risks for diabetes complications. The treatment appeared to be safe, with no severe side effects noted. According to Mynarek's team, their research supports the notion "that a low-grade persistent virus infection is an underlying disease mechanism, and that type 1 diabetes may be prevented by development of new vaccines." The researchers concluded that "further studies should be done at an earlier stage in the disease process, to evaluate whether antiviral treatment could delay the progression of beta-cell damage leading to clinical type 1 diabetes." https://consumer.healthday.com/type-1-diabetes-2665779376.html XX Also at EASD, an update on once a week insulin icodec for the treatment of type 1 diabetes. While several other studies have investigated once-weekly insulins in type 2 diabetes, this was the first data to be presented from a large-scale phase 3 study in type 1 diabetes. The study, ONWARDS 6, included 582 people with type 1 diabetes who received either insulin icodec or insulin degludec. Participants had an average age of 44 years and an average diabetes duration of 20 years. Both the icodec and degludec group received basal insulin in combination with mealtime insulin (insulin aspart, or NovoLog) over a period of 57 weeks. Overall, participants treated with once-weekly icodec and once-daily icodec had similar reductions in A1C of -0.5%, suggesting that this new insulin may offer another option for treating type 1 diabetes. What were the key findings? This study showed that insulin icodec was effective at reducing A1C in people with type 1 diabetes, although icodec did lead to higher rates of hypoglycemia compared to degludec. Researchers are still investigating some questions related to the hypoglycemia events that occurred in this trial, such as how the time of injection and exercise may affect hypoglycemia. https://diatribe.org/once-weekly-insulins-type-1-diabetes-latest-research-update XX XX Vertex Pharmaceuticals says a third type 1 patient no longer needs insulin after it's investigational stem cell-derived therapy VX-880, being assessed for type 1 diabetes. Two patients who had been followed for at least 12 months likewise met the study's endpoint of the elimination of serious hypoglycemic events (SHE) between 90 days and 12 months. Tuesday's results follow an earlier data drop in June 2023, detailing the first two patients

Dexcom's Chief Operating Officer Jake Leach talks to me about G6, G7, trends in CGM, what the company has its eye on next and answers a lot of your questions. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

Bonus episode! Rob Howe is the host of Diabetics Doing Things. He's also one of the speakers at my Mom's Night out event coming up in just over two weeks Outside of Dallas, in Frisco Texas. He's been going a lot of cool stuff and we were just catching up.. and I thought it would be fun to record a conversation about everything the two of us are working on. So here's that chat, very little editing and no commercials. Our regular episodes of course air on Tuesdays – next week's will be late in the day or maybe Wednesday morning. I'm talking to Dexcom at EASD European Assoc for the Study of Diabetes on Tuesday, so we'll turn it around as quickly as possible. Ok, as always, This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

Off to college, just for caregivers! Stacey took part in a webinar panel hosted by The Diabetes Link to talk about advice and experience all around sending young adults with type 1 diabetes away to school. She's joined by Anna Sabino, CDCES of Finding Smiles Coaching. The panel is hosted by Diane Rose, director of programs for The Diabetes Link. A transcript is below Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: a new CGM from Medtronic is approved in Europe, semaglutides for people newly diagnosed type 1 may make a huge difference, a look at Keto diet for kids, Apple teases non-invasive glucose monitoring and Dexcom U is back! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected] Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX Our top this story this week a new CGM from Medtronic gets approval in Europe. It's called Simplera – an all in one disposable CGM– no fingersticks and no over-tape, which is new for Medtronic. Simplera is integrated with the InPen™ smart insulin pen, which provides real-time, personalized dosing guidance to help simplify diabetes management. Medtronic will begin a phased launch at the European Association for the Study of Diabetes (EASD) 59th Annual Meeting in Hamburg, Germany on Oct. 2-6, 2023. Simplera™ is indicated for ages 2+ and compatible with iOS and Android. Simplera™ is not approved by the FDA and is limited to investigational use in the U.S. Medtronic's automated insulin delivery (AID) system integrated with this next-generation sensor is currently under review for CE Mark and is not commercially available in the U.S. or in Europe. I've reached out to Medtronic – we'll learn more soon. https://news.medtronic.com/2023-09-21-Medtronic-Diabetes-announces-CE-Mark-for-new-Simplera-TM-CGM-with-disposable-all-in-one-design XX A small study and a long way to go here, but a weekly dose of semaglutide, helped seven out of 10 patients newly diagnosed with type 1 diabetes stop taking insulin after three to six months. Semaglutide is the key ingredient in Ozempic.. approved for type 2 and Wegovy, approved for weight loss. It's also thought to tamp down the inflammation that can lead to the destruction of insulin-producing cells. He noted previous research has shown that patients with newly diagnosed type 1 diabetes still have the ability to make some of their own insulin, so the team tested semaglutide in patients within three months of their diagnosis. All ten patients were taking meal time and long acting insulin. After three months, all of them came off meal time insulin, and seven stopped basal insulin. Much more study needed here.. interestingly. Ozempic's maker, Novo Nordisk noted it didn't sponsor this study and isn't pursuing trials of semaglutide for type 1 diabetes itself, https://www.cbsnews.com/philadelphia/news/semaglutide-ozempic-wagovy-type-1-diabetes-insulin-study/ XX a widely used diabetes drug that controls blood sugar can also prevent muscle atrophy and muscular fibrosis—which can help the elderly bounce back faster from injury or illness. Researchers from the University of Utah Health have found that Metformin has surprising applications on a cellular level. Their findings were published in the journal Aging Cell. "We saw two things in our study," Drummond says. "When participants took Metformin during a bed rest, they had less muscle atrophy. During the recovery period, their muscles also had less fibrosis or excessive collagen. That build-up can make it harder for the muscle to properly function." https://scitechdaily.com/researchers-discover-surprising-side-effect-of-common-diabetes-drug/ XX Researchers at the Massachusetts Institute of Technology (MIT) say they have created a device for people with type 1 diabetes that may help produce insulin when needed. Their findings were published on September 18 in The Proceeding of the National Academy of Science. The MIT engineers reported that the small implantable device could carry hundreds of thousands of insulin-producing islet cells. Previous devices made for the same purpose failed and stopped producing insulin because they ran out of oxygen needed to create the insulin. To combat this, the scientists created an oxygen factory on the device, allowing it to generate oxygen by splitting water vapor in the body. The researchers said the device could potentially replace insulin injections in people with type 1 diabetes. Dr. Caroline Messer, an endocrinol

This week, it's one thing to push yourself when you live with type 1 diabetes.. we talk a lot about extreme athletes with T1D, but it's another thing to live with diabetes when others rely on you for their safety. Sarah Janin is an outdoor adventure guide for sports like rock climbing and ice climbing and avalanche education. Sarah was diagnosed with type 1 as a toddler, in a time before meters, let alone CGMs, and is incredibly honest about her struggles. She's thriving with diabetes now and she shares what she does to keep herself and her clients safe in the outdoors that she absolutely loves. More about Sarah here This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Moms' Night Out Info Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

Most of us wouldn't think twice about using someone else's emergency glucagon if our child or another adult needed it. But that's something a school nurse or other health care provider could lose their license over. Now, some states are passing legislation to make it easier for anyone to use any one's rescue glucagon. We talk to Georgia State Rep. Doug Stoner and his wife, Trip Stoner, a long-time diabetes advocate who lives with type 1 about what they were able to get passed in their state, what you can do to take action in yours, and what they're planning next to help people with diabetes. Find your legislators here Read Georgia's glucagon bill here Contact Doug here: [email protected] Moms' Night Out Registration is OPEN Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: Abbott acquires Bigfoot, a new study looks at low-dose aspirin to prevent type 2, researchers look into whether the AI ChatGPT can answer FAQs about diabetes, Beyond Type Run is back for the NYC Marathon, and more! Our previous episode with Bigfoot Biomedical: https://diabetes-connections.com/?s=bigfoot Join us for Moms' Night Out! (use promo code School30 to save) Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Learn about Edgepark Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected] Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX Our top story this week – Abbott scoops up Bigfoot Biomedical. The deal is expected to close later this year – no financial terms yet disclosed. Abbott and Bigfoot have worked together since 2017 on a connected insulin pen system. Bigfoot Unity exclusively works with Abbott's FreeStyle Libre® Long time listeners will recall that Bigfoot was founded in 2015 around serving people with type 1 diabetes with a closed loop pump system that Byran Mazlish had developed for his wife and son. Mazlish was very secretive at first about the algorithm – this was before people were sure the FDA wouldn't crack down on them – so a journalist nicknamed him Bigfoot. Along the way, the company pivoted to CGM connected SmartPens. I believe Bigfoot was my third interview, back in 2015 – I'll ink up all of the interviews I've done with them in the show notes. https://diabetes-connections.com/?s=bigfoot https://www.prnewswire.com/news-releases/abbott-to-acquire-bigfoot-biomedical-furthering-efforts-to-develop-personalized-connected-solutions-for-people-with-diabetes-301918254.html XX Low-dose aspirin reduces the risk for type 2 diabetes among older adults and slows the increase in fasting glucose levels over time, new research finds. The data come from a secondary analysis of ASPREE, a double-blind, placebo-controlled trial of healthy adults aged 65 years or older, showing that 100 mg of aspirin taken daily for about 5 years did not provide a cardiovascular benefit but did significantly raise the risk for bleeding. It's a big study, more than 16-thousand people. This new analysis shows that individuals taking aspirin had a 15% lower risk for developing type 2 diabetes and that the medication slowed the rate of increase in fasting plasma glucose, compared with placebo, during follow-up. However, lead author Sophia Zoungas, MBBS, PhD, head of the School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia, says, "Major prescribing guidelines now recommend older adults take daily aspirin only when there is a medical reason to do so, such as after a heart attack… Although these new findings are of interest, they do not change the clinical advice about aspirin use in older people at this time." https://www.medscape.com/viewarticle/996058 XX A class-action lawsuit filed against Medtronic (NYSE: MDT)+ alleges that the company's insulin delivery devices shared patient data with third parties. The lawsuit — filed by the plaintiff "A.H." in U.S. District Court in Central California — levels allegations against Medtronic and its MiniMed and InPen devices. It addresses MiniMed's transmission and disclosure of personally identifiable information and protected health information to Google and other third parties. Per the lawsuit, the data was transmitted via tracking and authentication technology, including Google Analytics, Crashlytics, Firebase Authentication and related tools. A.H. says these technologies, installed on the website and/or mobile applications, include the InPen iOS and Android applications. "Information about a person's health is among the most confidential and sensitive information in society, and its mishandling can have serious consequences, including embarrassment, discrimination, and denial of insurance coverage," the lawsuit reads. A Medtronic spokesperson issued the following statement via email: We have strong processes, technologies, and people in place to safeguard and protect our information and systems, the information of our business partners, and most importantly, the privacy and safety of th

This week, a new project to show an adventurous side of diabetes. a documentary about extreme athletes with type 1. The film makers are interviewing snowboarders, kayakers and professional athletes like Indy Driver Conor Daly and Soccer's Jordan Morris. Director Dylan Leonard talks to me about why he wanted to make this movie – he lives with type 1 – how they're going about it and why he thinks – in an age when we can see people with T1D doing all sort of amazing things – like playing in the NFL or serving on the Supreme Court – this type of film is still needed. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Breaking Limits GoFundMe page There's another T1D-focused movie fundraising right now as well. Check out "The Cost" here DOFFLEs (Dads of Friends for Life) info here: https://www.facebook.com/CWDiabetes Learn more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

Meet three young adults who are all in the spotlight AND have type 1 diabetes. NFL player Chad Muma, actor Mary Mouser, and professional race car driver Ryan Reed took part in a panel discussion at this summer's Friends for Life conference. The moderator is CNN correspondent Oren Liebermann, who also lives with T1D. I attended this panel in person and thought it would be fun to bring to a wider audience. One of the things you don't hear is a short film about Chad Muma that was shown at the start of the panel.. it's a great look at how he kept his dream of playing in the NFL going after his diagnosis. You can watch it here: https://www.tandemdiabetes.com/resources/community/team-tandem/tandem-ambassadors/chad-muma Note: Mary Mouser, Chad Muma, and Ryan Reed have compensation agreements with Tandem Diabetes Care. Individual experiences may vary. RX ONLY. The t:slim X2 insulin pump with Control-IQ technology is indicated for patients with type 1 diabetes, 6 years and older. BOXED WARNING: Control-IQ technology should not be used by people under age 6, or who use less than 10 units of insulin/day, or who weigh less than 55 lbs. For full safety information, visit: https://bit.ly/2OKAQsw Don't miss Moms' Night Out - a new event just for moms of children with diabetes: https://diabetes-connections.com/events/ Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: Amazon Pharmacy will automatically apply insulin coupons, a new study shows A1Cs are going down for people with T1D who have access to technology, pollution and gestational diabetes study and a wild study that looks at how a parasite might help prevent type 2. Don't miss Moms' Night Out! Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected] Transcript: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX Amazon's online pharmacy will automatically apply manufacturer-sponsored coupons to more than 15 insulin and diabetes medicines to help patients access discounts pledged by the drug industry. With the new program, patients using Amazon Pharmacy will no longer have to search for and manually enter coupons from the three largest insulin makers, Novo Nordisk (NOVOb.CO), Eli Lilly (LLY.N), and Sanofi (SASY.PA), to lower the cost of their insulin to as little as $35 for a month's supply, the company said. Novo, Lilly and Sanofi announced in March that they would slash their insulin prices by at least 70% by or in 2024, but many reports some patients were finding it difficult to get already discounted generic insulin from pharmacies at the promised lower price. Amazon Pharmacy will also automatically apply available discounts to diabetes-related medical devices from manufacturers Dexcom and Insulet, including continuous glucose monitors and pumps, as well as to other cardiometabolic medicines such as Novo's powerful weight-loss drug Wegovy. https://www.reuters.com/business/retail-consumer/amazon-pharmacy-automates-discounts-help-insulin-patients-get-pledged-prices-2023-08-15/ XX New study will look at Liver Targeted Insulin (LTI) in Type 1 diabetes.. Directing insulin action to the liver may help restore normal liver physiology for people with Type 1 diabetes, leading to better glucose control and overall health outcomes. Jeremy Pettus and a team of researchers are working to determine the mechanism of action and evaluate the safety profile of the Liver Targeted Insulin Pettus lives with type 1 and is an endocrinologist who is also the xx at TCOYD. "Living with Type 1 diabetes is extremely tough," said Pettus. "One of the major barriers to helping patients with Type 1 diabetes achieve normal glucose levels is that injected insulin simply does not get to the 'right' places. Normal insulin has its main effects in the liver, but patients with Type 1 diabetes must inject insulin into the fat tissue. Doing so makes the insulin act very slowly, can lead to weight gain and can cause deadly low blood sugars. This project seeks to attach a molecule to insulin that can help direct it to the liver. In doing so, much of the normal physiology may be restored and patients may get better results." Pettus is working with the company Diasome to conduct a single center clinical study with 14 patients with Type 1 diabetes to test the safety, tolerability and effectiveness of the novel LTI. If this study finds that the LTI is active and preferentially targeting the liver, the findings could spur research and development efforts in the LTI space, leading to additional clinical trials and eventually a novel insulin available that could help improve clinical outcomes. https://today.ucsd.edu/story/2m-grant-drives-research-on-novel-insulin-in-type-1-diabetes XX Good news about A1c reduction in people with type 1.. but it's limited for those with access to technology. The new findings from a study involving patients at the Barbara Davis Center for Diabetes Adult Clinic between January 1, 2014, and December 31, 2021. They show that as technology use has increased, A1c levels have dropped in parallel. Moreover, progression from use of stand-alone continuous glucose monitors (CGMs) to automated insulin delivery systems (AIDs), which comprise insulin pumps and connected CGMs, furthered that progress. On the flip side, A1c levels rose significantly over the study period among nonusers of technology. "We cannot rule out provider bias for not prescribing diabetes technology among those with higher A1c or from disadvantaged socioeconomic ba

It's one of the biggest milestones in my family's experience with diabetes. Our son is off to college! I asked Benny to come on and talk about what's on his mind, how he's feeling and to answer your questions, including if he's going to tell people he has T1D. We also answer your questions about overnights, how we've prepared, our plan for share and follow and much more. I can't believe this day is here! This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Our previous episodes with Benny: https://diabetes-connections.com/?s=benny Don't miss Moms' Night Out - our next stops are in Texas, Rhode Island, & North Carolina Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

This week, figuring out which diabetes devices you want to use is hard enough.. but then you have to navigate insurance. There's a new effort to streamline the process - a platform called DiabetesWise that's available – for free - for patients and providers: Korey Hood is the founder of DiabetesWise and he lives with type 1. We've talked about DiabetesWise before – but this insurance option is new. We talk specifics about how it can help, who it's for and what else Korey has in store for the platform. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Our previous episode with DiabetesWise: https://diabetes-connections.com/?s=diabeteswise Learn more about Moms' Night Out! Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

For adults with type 1, an initial misdiagnosis of type 2 diabetes is unfortunately, all too common. What's perhaps more unusual is what happened to this week's guest who was correctly diagnosed by TikTok! Justin Eastzer talks to me about the community support he found even before he was correctly diagnosed, how it led him to creating his own diabetes videos and content – you may know him better as Diabetech, and how his experience with cancer as a very young adult shaped his life. Justin's Podcast This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Don't miss Moms' Night Out - a new event for moms of children with diabetes Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: a new pilot program will allow some pharmacists to prescribe CGMs, Georgia becomes the latest state to pass a law securing Glucagon for schools, new info about COVID-19 and new cases of T1D, insulin pump infusion set and skin reaction study, does kombucha tea lower blood glucose and more! Moms' Night Out early bird specials will end soon for Texas and Rhode Island! Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Find out more about Edgepark Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected] Transcription: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by AG1. AG1 helps you build your health, foundation first. XX New pilot program to allow pharmacists to prescribe CGMs. This comes from the American Pharmacists Association Foundation, with support from Helmsley Charitable Trust. While many patients with diabetes may not even have access to a primary care physician, the average person interacts with their community pharmacist 12x more often than their primary care provider. The program will launch in 20 community pharmacy practices across the U.S. There will be a 90-day enrollment period followed by 12 months of monitoring and management https://www.businesswire.com/news/home/20230720044367/en/The-APhA-Foundation-launches-patient-enrollment-for-a-program-to-expand-access-to-pharmacist-provided-continuous-glucose-monitoring-CGM-devices-and-services XX We told you recently about Mobi's approval, that's Tandem's tiny pump, billed as the world's smallest durable automated insulin delivery system. Convatec Group now saying they've partnered with Tandem on a new five-inch infusion set for the Mobi. Not a lot more information than that, but interesting because while Convatec makes infusion sets for just about every tubed pump, last year, Tandem acquired another infusion set developer, Capillary Biomedical. https://www.outsourcing-pharma.com/Article/2023/07/18/Convatec-to-manufacture-new-infusion-set-for-Tandem-Diabetes-Care XX New law in Georgia to make sure all schools have emergency glucagon on hand and that it can be used for any student. House Bill 440 took effect on July 1, 2023. It will allow public and private schools in Georgia to acquire and keep a supply of glucagon. It allows prescribers to provide standing orders or prescriptions for ready-to-use glucagon to schools so that this medication can be rapidly administered to students in an emergency. Schools will also be able to work directly with glucagon manufacturers or third-party suppliers to obtain the products for free or at fair market or reduced prices. In 2018 a school nurse in Illinois used another students glucagon on a different study having an emergency, breaking the law. It's since been changed in Indiana and now, in Georgia. Disclaimer: the state rep who sponsored this bill, Doug Stoner is married to my dear friend Trip Stoner who lives with type 1. https://www.thegeorgiavirtue.com/georgia-legislature/georgia-bill-to-help-schools-treat-hypoglycemic-emergencies-becomes-law/ XX I think most of us know this but good to see research on it. A new study shows skin reactions at insulin pump infusion sites are common among people with type 1 diabetes who use the devices and can lead to delivery failure. researchers at the University of Washington, in Seattle, used biopsies and noninvasive imaging to compare insulin pump sites with control sites in 30 patients. They found Several differences were found at pump sites in comparison with control sites, including fibrosis, inflammation, eosinophils, a disease-fighting white blood cell which indicated an allergic reaction here. The inflammatory response, they say, "may result in tissue changes responsible for the infusion site failures seen frequently in clinical practice." Nearly all patients (93.3%) reported itchiness at the site, and 76.7% reported skin redness. While the researchers think preservatives in the insulin or the makeup of the infusion sets are probably to blame, they admit they don't really understand it fully yet. https://www.medscape.com/viewarticle/995068 XX Very large new study seems to confirm that the COVID-19 pandemic precipitated a jump in cases of type 1 diabetes in children

It's almost time for back to school! How do you explain type 1 diabetes to students? I asked a preschool teacher whose daughter has t1d to talk about how to get the message through without scaring anyone. Laura Self also has a great book our for kids called Sweetie. Her daughter, Hannah, was diagnosed at age 8 and is now 20. She spent the spring semester in Europe this year. Laura and I talk about how we tried to help our children find independence, confidence, and responsibility with diabetes. Moms' Night Out is in three cities! Find out more before our early bird specials end. Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

This week, actress Jennifer Stone lives with LADA.. she decided to become a nurse and started her first ER job in March of 2020. I asked her what it was like knowing she had to take care of her own diabetes while also taking care of patients during a pandemic: You might know Jennifer best from her days on Disney's Wizards of Waverly Place… I caught up with her to talk about how she manages LADA, why she decided to become a nurse and still continue acting... and what's next for her dual careers. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. More about LADA More about Medtronic's InPen system Our previous episode with Jennifer Stone Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

Let's talk about menopause and type 1. It's hard enough to find information about this part of life for women without diabetes.. so when this week's guest started looking for research about T1D she wasn't too surprised to come up short: Dawnie Adams is a midwife who is determined to use peer support to push medical research forward. We talk about her experience, what she and her group are doing to support each other, how diabetes and menopause can have similar symptoms which just makes everything confusion.. and much more. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: a new insulin pump gets FDA approval, once-weekly basal insulin for type 2 gets through another trial, New Jersey caps insulin prices for some, possible link between ability to chew and glucose control, a landmark diabetes study moves on to aging and T1D, JDRF Children's Congress and more! Learn about Moms' Night Out - a new event for moms of children with diabetes Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected] Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by AG1. AG1 helps you build your health, foundation first. XX Our top story, Tandem's Mobi Pump is approved. The FDA cleared the tiny pump for people with diabetes ages six and up. Tandem says mobie is fully controllable from a mobile app and is the world's smallest durable AID system. It still has a button on the pump to dose and holds 200 units. You use the same infusion set as the current Tandem pumps and Mobi uses Control IQ. Limited release planned for late this year and fully available early 2024. https://www.drugdeliverybusiness.com/fda-clears-tandem-mobi-automated-insulin-pump/ XX Learning more about a newly approved therapy for type 1 diabetes called Lantidra. Two safety and efficacy studies found that 21 participants who took Lantidra did not need to administer themselves insulin for a year or more. Twelve of those participants did not need to take insulin for up to 5 years, and 9 did not need insulin for over 5 years. Lantidra is an allogeneic (donor) pancreatic islet cellular therapy. In other words, Lantidra uses cells taken — or isolated — from human organ donor pancreases. "In [a] subsequent process, the insulin-producing islets are purified from the rest of the pancreatic tissue using a density gradient. Once the islets are isolated, purified, and put for a short time in cell culture, the cell preparation is infused into the liver of the recipient," he explained. https://www.medicalnewstoday.com/articles/fda-approves-first-cellular-therapy-for-type-1-diabetes-what-does-it-do#How-does-islet-cellular-therapy-work? XX Once weekly basal insulin for type 2 gets through another trial. After 26 weeks of treatment and five weeks of follow-up, patients on weekly insulin icodec had significantly larger improvements in their HbA1C than those using daily insulin. Both groups had an extremely low rate of adverse events. These researches say next step is FDA evaluation. https://www.utsouthwestern.edu/newsroom/articles/year-2023/july-weekly-insulin-found-safe.html XX That's the idea behind Fractyl Health's treatment for type 2 diabetes—which could also be used for weight control. The Lexington, Massachusetts-based biotech company is in the early stages of developing a one-time gene therapy intended to lower blood sugar and body weight using the same mechanism as semaglutide. "You have this problem where you need to stay on therapy for efficacy," says Harith Rajagopalan, a cardiologist by training and CEO and cofounder of Fractyl Health. "That's the Achilles heel." The company wants to deliver an artificial gene to the pancreas that continuously produces the GLP-1 hormone so there's no need for weekly injections. The approach, called gene therapy, uses inactivated viruses to carry a therapeutic gene to pancreatic cells. (Viruses are used because of their natural ability to deliver genetic material to cells.) The company is aiming to begin an initial human trial by the end of 2024 https://www.wired.com/story/a-one-time-shot-for-type-2-diabetes-a-biotech-company-is-on-it/ XX Gov. Phil Murphy signed three bills into law Monday aimed at cutting the high cost of prescription drugs in New Jersey. The new laws will cap how much residents will pay for some popular medications such as insulin, prevent pharmacy benefit managers from engaging in practices that make drugs more expensive, and create a panel that will monitor prices set by pharmaceutical companies. One measure (S1614) would cap the cost of insulin, epinephrine auto-injector devices and asthma inhalers for state and local public workers enrolled in the State Health Benefits Program, the School Employees' Health Benefits Program and other stat

My son Benny is back from a four week trip halfway around the world with a non-diabetes camp program. He says it was amazing! To be honest, I had a really hard time with it. This week, we share how we prepared, what went wrong, how Benny deals with feeling different on these types of trips and a lot more. This episode first aired in August of 2021 Previous episodes with Benny: 14 years of T1D Benny & Stacey talk untethered and more on their way to the endo Talking about Control IQ & addressing kids' questions about diabetes Our 12 year diaversary Ten years of T1D - our whole family speaks up This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

This week, G7 updates – direct to watch announcements – and a lot more about what Dexcom sees as the next frontier in CGM. A conversation – from ADA – with the company's Chief Commercial Officer Teri Lawver. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: FDA approval for a pancreatic islet cell therapy to treat type 1, stem cell research moves ahead, big news from the ADA Scientific Sessions about what's next for medications like Mounjaro and a pill form of semaglutide. Dexcom announces a sensor for people with type 2 who don't use insulin, Libre moves ahead with Ketone monitoring and more. Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected] Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by the T1D Exchange a nonprofit organization dedicated to improving outcomes for the entire T1D population. XX Big week of news following the 2023 ADA Scientific Sessions conference. What follows is just the tip of the information iceberg, so please follow the links in the show notes to much more. -- XX Top story though isn't from ADA – but a new FDA approval.. for a pancreatic islet cell therapy to treat type 1. It's called donislecel, developed from cadaver donors and giving as a single infusion straight into the liver. Immunosuppression is required to maintain cell viability, just as it is required to support a transplanted kidney or other organ. Approval was based on what seems to be a very small study – 30 people with type 1 who had hypoglycemic unawareness and who received between one and three infusions of donislecel. After one year, 11 people did not need to dose insulin.. 10 stayed that way for more than five years. But five people in the study were not able to stop dosing insulin at all. This method is different from what Vertex and Sernova are trying to do with stem cell therapy. https://www.medscape.com/viewarticle/993854 XX Vertex moves forward on their clinical trial of islet stem cell therapy. All six patients treated with VX-880 had undetectable fasting C-peptide (endogenous insulin secretion) at baseline, a history of recurrent SHEs in the year prior to treatment and required an average of 34.0 units of insulin per day. Following treatment, all six patients demonstrated endogenous insulin secretion, improved glycemic control as measured by HbA1c, improved time-in-range on continuous glucose monitoring, and reduction or elimination of exogenous insulin use. Two patient are completely insulin independent after one year – with an A1C of 5.3 compard to 8.6 at baseline.. the other 6.0 with a 7.6 at baseline – again the "after" number is without taking insulin. As a result of these safety and efficacy data in Parts A and B, the independent data review committee has recommended moving to Part C of the trial, which allows for concurrent dosing of patients at the full target dose of VX-880. https://www.businesswire.com/news/home/20230623446641/en/Vertex-Presents-Positive-VX-880-Results-From-Ongoing-Phase-12-Study-in-Type-1-Diabetes-at-the-American-Diabetes-Association-83rd-Scientific-Sessions XX Sernova also reports good results with their cell pouch system. Five of the six patients who have completed implantation continue to experience insulin independence for periods ranging from six months to more than three years. The sixth patient only recently completed the protocol-defined islet transplants.. so no results yet. There is a second group testing a larger cell pouch. https://www.drugdeliverybusiness.com/sernova-interim-data-cell-pouch-system/ XX Big news from ADA about all of the type 2 and obesity drugs you've likely heard about.. here are some headlines: SURMOUNT-2 clinical trial evaluating tirzepatide – brand name Mounjaro - for weight loss in adults with obesity or overweight and type 2 diabetes. Average weight loss was 15.7% at the highest dose, with many other health benefits such as lower A1C levels; reduction in waist circumference, and body mass index; and improvements in cardiometabolic disease risk factors such as lipid levels, cholesterol, and blood pressure. That 15 percent weight loss was about 34 pounds and the a1c reduction for half of those in the study went down to 5.7 which is considered nondiabetic. Mounjaro is currently approved for type 2 and the FDA could approve Mounjaro regardless of diabetes status later this year. https://diatribe.org/new-lilly-trial-results-show-big-weight-loss-re

LADA is a form of diabetes that is often mistaken for type 2 but needs to be treated much more like type 1. As you can imagine, getting the diagnosis wrong is dangerous. This week's guest, Jacqueline Haskins, says she got lucky. A friend said her symptoms sounded more like Latent Auto Immune Diabetes in Adults than like Type 2. Jacqueline is the author of Kick Ass Healthy LADA where she shares research, advice and her own story. She's an aquatic biologist and an award winning author. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Here are our earlier episodes around LADA Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

Katie Bone is the youngest ever American Ninja Warrior Women's National winner! She is also a nationally ranked rock climber and has her eyes on the Olympics. Katie was diagnosed with type 1 at age eleven and is now seventeen. We talk about her big win, a recent injury and what she's looking forward to next. She also answers a lot of your questions about managing T1D during training and competitions. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. More about Katie here: https://katiebone.com/ Watch Katie's NInja Warrior win: https://www.youtube.com/watch?v=i3Jlvc3OwLw Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: FDA warning about compounded versions of semaglutides like Wegovy and Ozempic, new research on what people with diabetes who start Go Fund Me campaigns are asking for, Tandem's CEO gives an update on Dexcom G7 and Libre integration, follow-up on the French Open player denied insulin on the court, and more! Here's more info about Mom's Night Out: https://bit.ly/DMomsNightOut Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected] Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by Moms Night Out! Treat yourself to some time away with other moms who get it! XX The U.S. Food and Drug Administration is warning consumers not to use off-brand versions of the popular weight-loss drugs Ozempic and Wegovy because they might not contain the same ingredients as the prescription products and may not be safe or effective. Agency officials said this week that they have received reports of problems after patients used versions of semaglutide, the active ingredient in the brand-name medications, which have been compounded, or mixed in pharmacies. Officials didn't say what the problems were. The trouble is that those versions, often sold online, contain a version of semaglutide that is used in lab research and has not been approved for use in people. As of May, Ozempic and Wegovy remain on the FDA's list of drug shortages. When drugs are in short supply, compounding pharmacies are permitted to produce versions of those medications. Consumers should only use drugs containing semaglutide with a prescription from a licensed health care provider and obtained from a state-licensed pharmacy or other facilities registered with the FDA, the agency said. https://time.com/6284497/fda-warning-ozempic-wegovy/ XX ZVHER-ehv pronounce https://www.youtube.com/watch?v=u8spdvgpIzs French Open organizers reversed their initial decision denying Alexander Zverev access to insulin injections on the court. Initially they said he'd have to do his injections during off-court bathroom breaks, something players are limited to only two of. Zverev has lived with type 1 since he was three years old? And apparently there were complaints after he injected himself during his fourth-round match. Zverev said he was told it didn't look right when he injected himself on the court. "This is not a clever take because if I don't do it, my life will be in danger. But they said it looks weird," he said. And it prompted a response from type 1 diabetes research charity JDRF. In an open letter, the charity said: "We would like to emphasise that insulin administration is an essential aspect of type 1 diabetes management, and it should be treated with the same respect and understanding as any other medical intervention. "It is critical that athletes with diabetes, like Mr. Zverev, are given the necessary accommodations and support to effectively manage their condition while competing. This includes the ability to administer insulin when required, as recommended by their healthcare professionals." XX Many people with diabetes in the United States have turned to crowdfunding to pay their medical bills, even though a quarter of patients sampled had insurance, according a new study by Duke University researchers. In the United States, more than 40% of patients with diabetes struggle to pay their medical bills. Among those patients, more than half — 56% — have either delayed or foregone care entirely, Caroline E. Sloan, MD, MPH, a primary care physician at Duke University School of Medicine, and colleagues wrote. One estimate suggested that the average patient who is dependent on insulin and has insurance spends about $4,800 every year on physician visits, supplies, medications, hospitalizations and lost wages — the equivalent to 15% of the median U.S. per capita income. They evaluated 313 GoFundMe campaigns describing patients' medical situations, expenses and fundraising goals. The researchers included an oversampling of type 1 diabetes campaigns so they could have roughly even proportions of type 1 and non-type 1 diabetes campaigns "and ensure a wide breadth of experiences." Sloan and colleagues found that the median fundr

Medications like Ozempic, Wegovy and Mounjaro are getting a lot of attention. What are they? How can they help people with type 1 and type 2? Should you think about taking one? After all, the weight loss component alone sounds amazing. This week, Stacey talks with Dr. Steve Edelman, who lives with type 1 and heads up Take Control of Your Diabetes – TCOYD – a not-for-profit organization with the goal of teaching and motivating patients in diabetes self-care. We go through the science behind these medications, who might think about taking them, and whether they live up to the hype. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. TCOYD ONE retreat info here More info about GLP-1 medications here Dr. Edelman's "Buongiorno" Mounjaro video here Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

The newly FDA-approved iLet Bionic Pancreas is the most hands-off automated insulin delivery system to be commercially available. At set up, all you enter is your weight and the only interaction with the pump is to announce meal size, no carb counting. Stacey talks with Beta Bionics CEO Sean Saint. We go through this pump system in lots of detail, talk about future plans – yes we'll talk dual chambered pump which is the original design here - and get a little philosophical about the idea behind a hands off system.. especially for those of us used to being much more in the driver's seat. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. More about Beta Bionics: https://www.betabionics.com/ Our previous episodes about the iLet here: https://diabetes-connections.com/?s=ilet One of many write ups of clinical trials with the iLet system: https://www.nejm.org/doi/full/10.1056/NEJMoa2205225 Stacey mentioned our episode with ConvaTec about infusion sets: https://diabetes-connections.com/the-seven-day-infusion-set-is-here-whats-next-from-convatec-infusion-care/ Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: Lilly becomes the first of the big three insulin makers to settle a class action lawsuit over pricing, the FDA approved Beta Bionics' iLet system, oral meds trialed for T2D seem to work as well as Ozempic injectable, Lego adds a T1D "friend" to their line and a big win for an American Ninja Warrior competitor with T1D. Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected] Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by VIVI Cap Keeps your insulin at the exact right temperature, even in extreme heat or cold. XX Our top story, Eli Lilly has agreed to pay $13.5 million to end a six-year, class-action lawsuit accusing the company of overpriced its insulin. As part of the settlement, Lilly has agreed to cap out-of-pocket costs for its insulin at $35 per month for four years. That's three months after Lilly said it would cut insulin prices to that level. The lawsuit was filed in 2017, against insulin makers Lilly, Novo Nordisk and Sanofi. Plaintiffs claimed the companies joined in an "arms race" to raise list prices of their meds while the "real" price to pharmacy benefit managers remained constant or in some cases dipped. Price increases of insulins that previously cost $25 per prescription were pushed up to $450, the suit said. The increases, taken in "lockstep," were "astounding and inexplicable," according to the class action lawsuit. Novo and Sanofi have yet to settle this case. https://www.fiercepharma.com/pharma/eli-lilly-inks-settlement-long-running-insulin-pricing-lawsuit XX The FDA is changing its draft guidance for industry regarding Antidiabetic Drugs and Biological Products. It's been 15 years since an update. Topics covered in the draft guidance include: Hemoglobin A1c (A1C), a measure of average blood sugar, remaining an acceptable primary efficacy endpoint The FDA now considering a reduction in the risk of hypoglycemia (low blood sugar) to be a clinically relevant outcome measure for diabetes drug clinical trials, when accompanied by either a reduction or maintenance of an acceptable A1C. The use of data collected by continuous glucose monitoring (CGM) systems, which allow for nonstop, passive glucose monitoring, in clinical trials to potentially support hypoglycemia labeling claims. Recent advancements in CGM technology have led the agency to recognize the advantages of data collected from these systems in clinical drug development. The FDA will be accepting comments on the guidance until August 24, 2023. https://www.appliedclinicaltrialsonline.com/view/fda-on-track-to-updates-diabetes-efficacy-endpoints-guidance XX The iLet bionic pancreas from Beta Bionics gets FDA approval for people with type 1 age 6 and up. This is a unique system in that it starts with only the user's weight and requires meal announcements – no carb counting – to automate blood sugar. It will launch with the Dexcom G6 CGM. You'll hear from the company CEO this Tuesday in our next episode where we do a deep dive into the system. https://www.medicaldevice-network.com/news/beta-bionics-fda-insulin-pump/ XX Researchers had observed an increased incidence of type-1 diabetes cases during the COVID-19 pandemic. Now, a new study has confirmed the link and established a temporal association between the development of type-1 diabetes in children and infection with the SARS-CoV-2 virus. The new study published in Jama Network was the first research that used data, which indicated if the type-1 diagnosed children previously had COVID-19 infection. The researchers found the likelihood to develop type-1 diabetes increased by 57% in children who had a confirmed COVID-19 infection, compared to those who did not have the infection. https://www.medicaldaily.com/covid-19-infection-increases-incidence-type-1-diabetes-children-study-469854 XX New oral medication from Pfizer seems to stack up well next to Ozempic for weight loss. New study looked at people with type 2 found danuglipron when given twice a day, lowered blood sugar in patients at all doses and reduced body weight at the highest dose after 16 weeks. The weight loss with danuglipron is of a similar magnitude to that observed in

This long-awaited Medtronic 780G is now FDA approved. It's been out for two years in Europe and has features that are a bit different from other commercially available automated insulin delivery systems in the US, including a target range down to 100. This week you'll hear from Heather Lackey, global medical education director for Medtronic Diabetes who also lives with type 1 and has used the 780G. We talk about what else this system can do – remember this is the one with the 7-day infusion set – and Stacey asks a lot of your questions. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. More info here: https://diatribe.org/medtronic-minimed-780g-approved-fda Lackey mentions a study where even with no meal boluses for three months, people stayed mostly in range. Here's that study: The Official Journal of ATTD Advanced Technologies & Treatments for Diabetes Conference Madrid, Spain—February 19–22, 2020. Diabetes Technology & Therapeutics. Feb 2020.A-1-A-250.http://doi.org/10.1089/dia.2020.2525.abstracts Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected] Rough Transcription: Stacey Simms 0:00 Diabetes Connections is brought to you by The only Ultra rapid acting inhaled insulin by Omni pod five, the only tubeless pump that integrates with Dexcom G six mi Dexcom G seven powerful simple diabetes management. This is Diabetes Connections with Stacey Simms. This week, the long awaited Medtronic 780 G is now FDA approved. It's been out for two years in Europe and its features that are a bit different from other commercially available systems in the US, including a target range down to 100. Heather Lackey 0:44 And it's just been proven to do so successfully without really increasing a lot of time below range. You know, what will the next system lead up? Will it be below 100? I don't know. But it's so nice to be waking up with glucose levels that are so much closer to someone without type 1 diabetes with this lower target. Stacey Simms 1:05 That's Heather Lackey, global medical education director for Medtronic. She also lives with type one, we talk about what else the system can do remember if this is the one with the seven day infusion set, and I ask a lot of your questions. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Welcome to another week of the show. Always so glad to have you here. You know, we aim to educate and inspire about diabetes with a focus on people who use insulin. I'm your host, Stacey Simms, and we are getting some big FDA approvals. Along with the Medtronic 780 G, we got word that beta bionics islet will soon be commercially available. As I am recording this I do have an interview set up with the beta bionics CEO. If all goes to plan that will be our show next week. Real quick, while the original islet dual chambered pump was not what was in front of the FDA, the pump that has been approved has some really interesting features. It's unique in that there are no steps to the programming. When you get your pump, you're not putting in basal rates or insulin sensitivity factors or anything like that. All you do is put your weight in. But that is for next week. You can follow me on social media. We've already shared some information about the islet and I've done many episodes in the past if you want to listen to those to get an idea of what was approved, but this week, we're talking about the Medtronic 780 G, as you likely remember Medtronic at the very first of what we now call a ID systems automated insulin delivery systems with their mini med 670 G and that was approved in 2017. We've been hearing about the 780 G for a long time. It was submitted in 2021. I've talked a lot about the delays in the in the news episodes. It has been approved in Canada since last year. It was approved in Europe in 2020. We're gonna go through lots of features of the pump, but you should also know that the sensor used with this system The Guardian four is approved with no finger sticks for dosing, which to me is one of the most significant changes. My guest to talk about all this is Heather lackey. She has been with Medtronic for more than 19 years. She delivers medical education strategy for insulin pump systems. She trains Medtronic education teams arou

When many diabetes tech companies are turning their attention to CGMs or closed loop systems, Josh Pittman has his eye on the basics: lancets. His company PIP, makes a new kind of smaller and thinner device for fingersticks. This week, we talk about why he thinks this is still necessary, why he's passionate about helping people overcome fingerstick fear and what his mother with type 2 taught him about why the basics are so important to long term care. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

On social media, Neil Greathouse is better known as "The Betes." He posts daily about diabetes on social media. It's a lot of work – and not his real job. I wanted to know why this is important to him. What is he hoping to accomplish? There is so much to Neil's story – he's become a diabetes educator – and he's an open book – he'll share about going into DKA not too long ago, a failed marketing effort with a big diabetes company and much more. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. My first conversation with Neil, from 2017: https://diabetes-connections.com/neil-greathouse-t1d-instagram-inspiration/ Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: The US Senate grills insulin makers about keeping the price where it is, two studies look at the impact of faster-acting insulins, a new study looks out temperature and insulin storage, researchers examine CGM access and health outcomes, and more Check out Moms' Night Out with three new dates on the calendar! Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected] Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by Moms Night Out - Treat yourself to some time away with other moms who get it. Our next stops this fall in Providence, RI and Frisco TX. XX Our top story this week, big Senate hearing on insulin.. The three insulin makers recently cut their list prices by around 70%. The Senate Committee on Health, Education, Labor and Pensions pressed industry leaders and all three – Lilly, Novo Nordisk and Sanofi - committed to "keeping their drugs affordable," But asked whether the companies would no longer raise prices on their existing insulins, only Lilly sai yes. The Sanofi and Novo Nordisk chiefs did not. Sen. Markwayne Mullin, R-Oklahoma, called PBMs "the fox guarding the henhouse," going after the executives for essentially "rebating themselves." He said the situation "isn't working for America." "This committee is going to stay on this issue," Senator Bernie Sanders said Wednesday. "We need profound change in the industry and in PBMs." https://www.fiercepharma.com/pharma/bernie-sanders-led-senate-committee-holds-pharma-chiefs-and-pbm-execs-feet-fire-insulin XX Not a big difference between fast-acting insulin aspart and standard insulin. New study using hybrid closed-loop insulin delivery system found that faster acting Fiasp did not offer any additional glycemic benefits compared with standard insulin aspart – Novolog - and participants had more cases of hyperglycemia with ketosis with the Fiasp. The study cohort had a baseline HbA1c of 7.2% and a time in range of 63.9% at the start of the trial. Of the cohort, 76% was using a hybrid closed-loop insulin delivery system at enrollment. There were no cases of severe hypoglycemia or DKA during either intervention. https://www.healio.com/news/endocrinology/20230508/time-in-range-similar-with-fastacting-vs-standard-insulin-for-young-kids-with-diabetes XX On the other hand, people with type 2 diabetes saw more time in range with faster acting insulin. These were adults with type 2 on basal bolus MDI along with CGM. The insulins here with Lyumjev and humalog. https://link.springer.com/article/10.1007/s13300-023-01400-w XX New study confirming that insulin doesn't have to be refrigerated as strictly at package instructions. These researchers took 6 different bands and types of insulins and stored them – quote - unopened for 1–4 months in non-refrigerated conditions in a real-world setting during the summer in India, all compared with control samples of each insulin, which remained refrigerated. Insulin vials were stored in watertight bags. Bags were placed in either an open plastic container stored on a high shelf or in a cupboard, or in clay pots with a separate water compartment. All storage containers were placed in shaded areas The temperature was measured every 15 min by electronic data loggers. The mean maximum temperatures were between 86 and 94 degrees. Most of the insulin stayed fine for two months and much of it for four months. Every study I talk about is linked up at this episode's homepage at d-c dot com with more specifics. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(23)00028-1/fulltext?fbclid=IwAR1J2Y2JLZNHTvlPwtCo7t-wA60zhFMRvx2DEc7sujaFOX1pKc_-RbjhnL0 XX Not so shocking conclusion that increasing access to CGMs – regardless of ethnicity and insurance status – can improve outcomes. Despite higher rates of complications among T1D youths from lower-income backgrounds, diabetes technology is 50% lower among this group. Youths with public insurance have frequent interruptions to CGM access, which are associated with worsening HbA1C trends. Implicit biases and willingness to recommend diabetes technology to youths from underrepresented backgrounds are likely additional contributors

Actor Austin Basis has a juicy role in this final season of The Marvelous Mrs. Maisel; he plays Alvin, the head writer on the show within the show. Basis was diagnosed with type 1 at age nine back in the 1980s. It was a time before home blood glucose meters, let alone pumps and CGMs. He shares how he manages T1D during auditions and on the set and of course we talk about Mrs. Maisel! I had questions about the fashion, the plot, all night shoots and how this final season ends. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. My first episode with Austin Basis from 2018: https://diabetes-connections.com/actor-austin-basis-and-the-kinetix/ Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

Medicare has now expanded coverage for CGM use among people with type 2, in part because of studies by companies like Dexcom. We'll talk about those findings and learn more about the US release of the G7. Dexcom Chief Operating Officer Jake Leach gives us information on app updates, talks about CGM for people with type 2 and gestational diabetes, pump integration for the G7, smoothing – and what that means – and a lot more. More info about CGM and Medicare: From ADCES: http://www.radiomiw.com/press.html Dexcom Medicare coverage info: https://www.dexcom.com/en-us/g6-g7-medicare This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Moms' Night Out is back! Three cities are on the schedule: Learn more Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: after a long wait, the FDA approves Medtronics 780G and lifts their warning letter, Omnipod GO for people with type 2 gets approved, a look at insulin in pill form, a new way to treat overnight low blood sugars and lots more! Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected] Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by the T1D Exchange, make your voice heard and drive research that matters XX Buckle up there is a LOT going on XX Medtronic's Minimed 780G AID system gets FDA approval. This is for people aged 7 years and older who have type 1 diabetes. Medtronic will begin taking preorders on May 15, 2023. Users of the current MiniMed 770G will be eligible for free remote software upgrades. The 780G is currently available in 105 countries. It has been available in Europe since 2020 and in the UK since 2021. The biggest difference from other systems is that it can automatically administer bolus correction insulin doses every 5 minutes. It will also automatically adjust basal insulin The insulin pump's infusion set can be worn for 7 days, rather than 3 days as with the older system, and the glucose target level can be set as low as 100 mg/dL. In the pivotal US trial, overall, patients who used the 780G spent 75% of the time in ideal glucose range (70-180 mg/dL) and 1.8% of the time below that range. Overnight, the figures were 82% and 1.5%, respectively. With the glucose target set at 100 mg/dL and active insulin time set to 2 hours, patients spent 78.8% of time in range without increased hyperglycemia. https://www.medscape.com/viewarticle/991091 XX U.S. Food and Drug Administration (FDA) lifted Medtronic's warning letter sent in December 2021. The resolution of the warning letter follows ongoing remediation actions from the company and proactive actions to continue to strengthen its quality systems. All regulatory restrictions associated with the warning letter have been resolved. https://finance.yahoo.com/news/medtronic-diabetes-resolves-warning-letter-203000188.html XX FDA also approved Omipod GO, for people with type 2 who take daily injections of long acting insulin. Insulet says "Omnipod GO was designed to serve the more than three million people using basal insulin or transitioning to insulin therapy to treat their type 2 diabetes" Omnipod GO is a standalone system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. It's tubeless and waterproof just like a regular Omnipod but it's offered in seven different pre-programmed daily rates, ranging from 10 to 40 units per day, and operates without the need for a handheld device to control the Pod. It has been cleared for use with the following U-100 insulins: NovoLog®, Fiasp®, Humalog®, Admelog®, and Lyumjev®. The product was developed to serve people with type 2 diabetes earlier in their treatment journey by starting them on Pod therapy for their insulin delivery, rather than daily injections. If a patient becomes insulin-intensive, meaning they require both basal and bolus insulin, the transition to another Omnipod product would be seamless. Omnipod GO will have its US launch sometime next year. https://www.businesswire.com/news/home/20230424006026/en/Insulet-Announces-FDA-Clearance-of-Omnipod-GO%E2%84%A2-a-First-of-its-Kind-Basal-Only-Insulin-Pod-Further-Simplifying-Life-for-People-with-Type-2-Diabetes XX Senseonics says the first pediatric study participant has received an Eversense 365-day CGM insertion. The E3 180 day implantable CGM got FDA approval in February last year. Dr. Francine Kaufman, Senseonics CMO, said expanding to a pediatric population represents a "priority" for the company. Positive results could further extend the company's reach across the global diabetes community, she added. The company also intends to utilize study data to submit for an integrated CGM (iCGM) designation in 2023. Senseonics holds an FDA investigational device exemption (IDE) to expand the trial to pediatric patients. These patients — between 14 and 18 years old — first enrolled in the second quarter of 2023. https://www.drugdeliverybusiness.com/senseonics-first-pediatric-cgm-inserti

Long thought an impossible, development people with type 1 diabetes are now working as commercial airline pilots. The very first to be certified in the US , Pietro Marsala says he decided to forge ahead while working as a flight instructor, taking inexperienced student pilots up while he was in control. Pietro will share what happened next, how a mountain of data gradually won of skeptics, his in flight diabetes routine and what he's up to now. You might be a passenger on his next flight! This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Follow Pietro on Instagram: https://www.instagram.com/flytype1/?hl=en FAA requirements for pilots who dose insulin: https://www.faa.gov/ame_guide/dec_cons/disease_prot/itdm More about Pietro Marsala: https://www.healthline.com/diabetesmine/first-commercial-pilot-type-1-diabetes Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: [email protected]